In two PASC cohorts, CRP and IL-6 did persist at high levels after recovery from severe COVID-19, but this was not seen following mild COVID-19 (9, 45), despite equivalent risk for PASC, at least based on some phenotypes, in the latter. This evidence concerns the gene IL6 and long COVID-19.